September 8, 2022

AstraZeneca Pharmaceuticals: Latest Data on Management of Factor Xa Inhibitor-Related Acute Major Bleeding

Tuesday, October 10
2:30 pm – 3:15 pm
Location: Expert Theater 2


Latha Ganti, MD, MS, MBA, FACEP

Theater Information


  • Recognize the impact of apixaban- and rivaroxaban-related major bleeding.
  • Review a reversal agent that restores FXa activity and thrombin generation in patients with apixaban- and rivaroxaban-related acute major bleeding.
  • Discuss clinical trial and real-world evidence of this reversal agent for apixaban- and rivaroxaban-related major bleeding.

Supported by AstraZeneca

September 29 - October 2

You've Built a Life in Emergency Medicine

Reconnect with friends from every chapter of your career at ACEP24

Register TodayBook Hotel

[ Feedback → ]